Literature DB >> 3593412

Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies.

D M Grant, M E Campbell, B K Tang, W Kalow.   

Abstract

The nature of the cytochrome P-450-dependent enzyme reactions giving rise to four primary metabolites of caffeine was investigated using microsomes isolated from livers of human kidney donors. Metabolite formation proceeded at a lower rate than that predicted from in vivo caffeine elimination half-lives, as has been observed in other species using this compound as a substrate in microsomal incubations. Kinetic experiments indicated that the formation of each of the N-demethylated metabolites paraxanthine, theobromine and theophyline was mediated by both a high- and a low-affinity catalytic site over a substrate concentration range from 0.05 mM to 80.0 mM, although only the high-affinity component is likely to be of any importance at normally encountered in vivo caffeine concentrations. 7-Ethoxyresorufin and acetanilide, selective substrates for two polycyclic aromatic hydrocarbon (PAH)-inducible isozymes of cytochrome P-450 in the mouse (P1-450 and P3-450, respectively) were each able to inhibit competitively the formation of caffeine metabolites by human liver microsomes, while caffeine could in turn similarly inhibit the biotransformations of these two compounds. The isozyme-selective P-450 inhibitor alpha-naphthoflavone (ANF) potently inhibited the high-affinity component of caffeine N-demethylations, while 1-phenylimidazole (PI) was a more potent inhibitor of the low-affinity component. The inhibition studies also indicated that the formation of 1,3,7-trimethyluric acid was mediated by both ANF-sensitive and PI-sensitive sites. Taken together, the data support suggestions from in vivo studies that a PAH-inducible isozyme of cytochrome P-450 plays a significant role in the biotransformation of caffeine in man.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3593412     DOI: 10.1016/0006-2952(87)90078-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

1.  Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.

Authors:  M A Butler; M Iwasaki; F P Guengerich; F F Kadlubar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; S Krahenbuhl; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ.

Authors:  J J Lozano; E López-de-Briñas; N B Centeno; R Guigó; F Sanz
Journal:  J Comput Aided Mol Des       Date:  1997-07       Impact factor: 3.686

Review 4.  Drug interactions with proton pump inhibitors.

Authors:  P Unge; T Andersson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

5.  Effects of capsaicinoids on oxidative metabolism of caffeine in isolated rat hepatocytes.

Authors:  A Bouraoui; J L Brazier; H Zouaghi; B Ribon; E Vermeulen; M Desage
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

Review 6.  Caffeine in tea Camellia sinensis--content, absorption, benefits and risks of consumption.

Authors:  A Gramza-Michałowska
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

Review 7.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 8.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

9.  Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults.

Authors:  C Cazeneuve; G Pons; E Rey; J M Treluyer; T Cresteil; G Thiroux; P D'Athis; G Olive
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

10.  Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro.

Authors:  U Fuhr; E M Anders; G Mahr; F Sörgel; A H Staib
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.